Resyca is redefining drug delivery through innovative soft mist inhalation and nasal spray technologies.

Set your therapies apart with Resyca’s IP‑protected soft mist technology. Benefit from efficient delivery to the lungs or targeted administration to the nasal cavity.

Proprietary platforms, including the Pre‑Filled Syringe Inhaler (PFSI®) and Ultra Soft Nasal Spray, generate low‑velocity aerosols optimized for improved lung and nasal deposition, while supporting patient usability and consistent dose delivery. These technologies are particularly suited for liquid formulations, including shear‑sensitive biologics and lipid nanoparticles (LNPs), addressing key technical challenges in today’s OINDP development.

Integrated end‑to‑end capabilities cover early development, device–formulation integration, clinical supply, and commercial manufacturing (including fill‑finish). This reduces development risk and simplifies execution for pharmaceutical and biotech partners. With advanced platform technologies and full lifecycle support, Resyca is a strategic partner for next‑generation, inhaled and nasal delivery programs, including innovative nose‑to‑brain (CNS) therapies.